Sai Life Sciences Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/arwckpnn9s6lwx0k94l0qiz4.pdf

Key Takeaways


Financial Performance

Siva Chittor: "If you ask me, would you maximize margins or optimize your growth overall, I would probably optimize my growth where I maximize my growth potential and optimize my margins and to stay steady around the 28%, 30%, but grow faster that would then get us into a dominant larger position."

Capacity Expansion & Capex

Krishna Kanumuri: "We are taking a technology first approach to our capacity addition rather than just adding capacity for the sake of adding capacity. We want to ensure that our capacity remains best in class as you see five years down the road, as opposed to having capacity to win projects immediately."

Demand Environment & Competitive Positioning

Siva Chittor: "The only way that we can kind of protect ourselves or minimize impacts against destocking is to make sure that you have a slightly larger portfolio and we are not concentrated on one or two products that then can impact our revenue."

Margin Philosophy & Trade-offs

Krishna Kanumuri: "If you over-optimize for margin, you potentially will be leaving market share never be able to scale and compete in the long term. So I think we have to be careful what we wish for."

New Modalities & Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginSustain 28% to 30% range while maximizing growthOngoing
Revenue growthBroad-based guidance of 15% to 20%Not specific to a particular year
CDMO/CRO mixRemain around 65-35% to 60-40%Ongoing, with year-to-year variability
Employee cost leverageOperating leverage on employee costs to continueInto next year
Unit 8 R&D Phase 1Commission ~200 fume hoods for discovery chemistryQ4 FY26
Process R&D buildingCommission, doubling total process R&D capacitySeptember '26
Peptide process development facilityExpand discovery and development peptide capabilities up to pilot scaleSeptember '26
OEB laboratoriesComplete, enhancing ADC capabilitiesOctober '26
Bidar capacity additionAdd 225 KLJune FY27
Bidar capacity additionAdd another 225 KL, ~70% total increaseQ4 FY27
Animal health Phase 1Complete, enabling validation activities for veterinary API productionMarch '27
New Hyderabad siteUp and running with non-GMP, peptide, and GMP capacity18-24 months
Provision reversalRemaining ₹18 crores to reverse as production progressesNot specifically in Q4 FY26
Biotech funding recoveryNo meaningful new company formation expectedAt least next 18-24 months

Key Metrics

MetricQ3 FY26
Revenue₹556 cr, +27% YoY vs ₹440 cr in Q3 FY25
CDMO revenue share~65% of total revenue, grew ~31% YoY
CRO revenue share~35% of total revenue, grew ~19% YoY
EBITDA₹191 cr, +54% YoY, margin of 34%
Profit after tax₹100 cr, +86% YoY
9M FY26 revenue₹1,590 cr, +43% YoY vs ₹1,115 cr in 9M FY25
9M FY26 EBITDA₹472 cr, +79% YoY, margin of ~30% vs ~24% in prior year
9M FY26 PAT₹245 cr, +199% YoY
EBITDA margin guidance28% to 30%, achieved ahead of schedule, expected to be sustained
Capex invested in FY26 to date~₹405 cr
Capacity utilization~60%
Late-phase and commercial molecules added in 9M FY267 molecules, 3 commercial and 4 Phase III
Top customer concentration~12% of total revenue
Provision reversal in Q3 FY26₹16 cr reversed, out of ₹34 cr provision taken in Q4 FY25